Aerovate Therapeutics is developing AV-101, a proprietary dry powder inhaled formulation of imatinib, to target the hyperproliferation of cells in the narrowed arteries of patients with pulmonary arterial hypertension (PAH). This approach aims to provide significant health improvements for individuals suffering from this rare and progressive cardiopulmonary disease.
Funding
$72.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SIFounders
Product
Problem
Pulmonary arterial hypertension (PAH) is a rare, progressive cardiopulmonary disease characterized by the narrowing of arteries in the lungs. Current treatments primarily address symptoms without targeting the underlying drivers of the disease.
Solution
Aerovate Therapeutics is developing AV-101, a proprietary dry powder inhaled formulation of imatinib, designed to target the hyperproliferation of cells within the narrowed pulmonary arteries of patients with PAH. By directly addressing this underlying cause, AV-101 aims to provide significant improvements in the health and lives of individuals suffering from this debilitating condition. The inhaled delivery method is intended to maximize drug concentration in the lungs while minimizing systemic exposure.
Target Audience
The primary target audience is individuals suffering from pulmonary arterial hypertension (PAH) and the healthcare professionals who treat them.
Features
- Proprietary dry powder inhaled formulation of imatinib
- Targeted delivery to the pulmonary arteries
- Designed to address the underlying hyperproliferation of cells in PAH
- Aims to improve patient outcomes by targeting disease drivers